PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair [PDF]
EMBO JournalTargeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a ...
Christina Andronikou +2 more
exaly +3 more sources
Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor [PDF]
FEBS Open BioPoly(ADP‐ribose) glycohydrolase (PARG) is a key enzyme involved in poly(ADP‐ribose) (PAR) degradation and is considered a potential anticancer target. We previously investigated resistance mechanisms to the PARG inhibitor PDD00017273 in human colorectal ...
Kaede Tsuda, Yoko Ogino, Akira Sato
doaj +3 more sources
Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer [PDF]
Clinical and Translational MedicineBackground Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease.
Cristina Queralt +14 more
doaj +2 more sources
PLoS ONE, 2016 Benzo(a)pyrene (BaP) is a ubiquitously distributed environmental pollutant and known carcinogen, which can induce malignant transformation in rodent and human cells.
Xuan Li +8 more
doaj +2 more sources
Frontiers in Pharmacology, 2019 Benzo(a)pyrene (BaP) is a polycyclic aromatic hydrocarbon that specifically causes cancer and is widely distributed in the environment. Poly (ADP-ribosylation), as a key post-translational modification in BaP-induced carcinogenesis, is mainly catalyzed ...
Yingbin Fu +2 more
exaly +3 more sources
PARG Mutation Uncovers Critical Structural Determinant for Poly(ADP-Ribose) Hydrolysis and Chromatin Regulation in Embryonic Stem Cells [PDF]
CellsPoly(ADP-ribosyl)ation is a crucial posttranslational modification that governs gene expression, chromatin remodeling, and cellular homeostasis. This dynamic process is mediated by the opposing activities of poly(ADP-ribose) polymerases (PARPs), which ...
Yaroslava Karpova +3 more
doaj +2 more sources
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination [PDF]
npj Breast CancerPARG plays an important role in cancer progression and immunoresponse, but its role in breast cancer is not yet fully elucidated. The advanced breast cancer is still a persistent challenge in clinical oncology.
Junnai Wang +9 more
doaj +2 more sources
PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential [PDF]
Journal of Translational MedicineBackground ATM deficiency is frequently observed in castration-resistant prostate cancer (CRPC). However, effective therapeutic vulnerabilities associated with this genetic alteration remain poorly defined.
Xuan Zhou +7 more
doaj +2 more sources
PARG regulates the proteasomal degradation of TARG1
Cell ReportsSummary: ADP-ribosylation (ADPr) is a reversible modification of macromolecules critical for the regulation of genome stability, stress responses, and proteostasis.
Joséphine Groslambert +15 more
doaj +2 more sources
Real‐World Effectiveness and Safety of Pegzilarginase Treatment in Arginase 1 Deficiency
JIMD ReportsPegzilarginase is the first disease‐modifying drug for arginase 1 deficiency. In clinical trials, pegzilarginase effectively normalised plasma arginine (pArg), which was associated with clinically relevant improvements in neuromotor outcomes.
Anaïs Brassier +10 more
doaj +2 more sources